The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to Proteostasis Therapeutics’ cystic fibrosis therapy PTI-428 — a…
Articles by José Lopes, PhD
Pulmonary hypertension increases the risk of cystic fibrosis patients’ lung function worsening, but is not a predictor of reduced survival,…
The U.K.’s Medicines & Healthcare products Regulatory Agency (MHRA) issued an alert to urge patients and healthcare professionals to…
A Phase 1 clinical trial testing Arch Biopartners’ AB569 for the treatment of antibiotic-resistant bacterial infections is now enrolling…
The U.S. Food and Drug Administration (FDA) gave a green light to human testing of ORC-13661, Â Oricula Therapeutics‘…
The interaction of ions and sugars called glycans can affect the mucus that lines airways — a finding that has implications for…
More than half of British babies born with cystic fibrosis today will reach the age of 50, according to a new…
The most influential cystic fibrosis advocacy groups in the United States and Europe have endorsed the idea of a Phase…
Multi-drug-resistant nontuberculous mycobacteria (NTM) can be found in the gastric juice and tubes that are used to feed some cystic…
The activity of Zerbaxa (ceftolozane/tazobactam, or C/T) alone or in combination with other antibiotics shows promise against multi-drug resistant (MDR)…